Clara Jundt and her team at Janssen R&D, in collaboration with Altis and UNC-Chapel Hill, conducted a study using human primary intestinal epithelial cells from multiple donors. Their aim was to determine if these cells could mimic a similar response and capture the genetic variability found in humans. The researchers treated the models with TNFα and IFNγ, revealing consistent responses across different donors. Additionally, they discovered that the JAK-STAT inhibitor tofactinib effectively blocked these responses in a dose-dependent manner.
Poster: Characterization of a novel human primary intestinal epithelial monolayer platform in response to a cytokine challenge
Ready to design your study?
TLR Signaling in IBD Begins at the Epithelium
Most of the excitement in inflammatory bowel disease right now points upstream. The field spent two decades blocking finished cytokines,…
Species Differences in Drug Absorption: The 63% That Became 3%
Here is a number that should stop any oral drug program cold. A compound absorbs at 63% in rats and…
Ester Prodrug Design for the Human Gut, Not the Cancer Line
Ester prodrug design is an exercise in controlled instability. You start with a molecule that has a real liability: poor…